EMEA-002669-PIP02-20

Table of contents

Key facts

Invented name
Lorviqua
Active substance
Lorlatinib
Therapeutic area
Oncology
Decision number
P/0006/2021
PIP number
EMEA-002669-PIP02-20
Pharmaceutical form(s)
Film-coated tablet
Condition(s) / indication(s)
Treatment of lung cancer
Route(s) of administration
Oral use
Contact for public enquiries
Pfizer Europa MA EEIG

Email: PIP_Enquiries@pfizer.com
Tel. +44 1304646607

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

Related content

How useful was this page?

Add your rating